Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b

✍ Scribed by Naoya Sakamoto; Mina Nakagawa; Yasuhito Tanaka; Yuko Sekine-Osajima; Mayumi Ueyama; Masayuki Kurosaki; Nao Nishida; Akihiro Tamori; Nishimura-Sakurai Yuki; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Shuhei Hige; Yoshito Itoh; Eiji Tanaka; Yoichi Hiasa; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami; Mamoru Watanabe; the Ochanomizu-Liver Conference Study Group

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 149 KB
• Volume: 83
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.22038

✦ Synopsis

Abstract

Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated‐interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy. The aim of this study was to investigate the relationship between IL28B polymorphism and responses to therapy in patients infected with genotype 2. One hundred twenty‐nine chronic hepatitis C patients infected with genotype 2, 77 patients with genotype 2a and 52 patients with genotype 2b, were analyzed. Clinical and laboratory parameters, including genetic variation near the IL28B gene (rs8099917), were assessed. Drug adherence was monitored in each patient. Univariate and multivariate statistical analyses of these parameters and clinical responses were carried out. Univariate analyses showed that a sustained virological response was correlated significantly with IL28B polymorphism, as well as age, white blood cell and neutrophil counts, adherence to RBV, and rapid virological response. Subgroup analysis revealed that patients infected with genotype 2b achieved significantly lower rapid virological response rates than those with genotype 2a. Patients with the IL28B‐major allele showed higher virus clearance rates at each time point than those with the IL28B‐minor allele, and the differences were more profound in patients infected with genotype 2b than those with genotype 2a. Furthermore, both rapid and sustained virological responses were associated significantly with IL28B alleles in patients with genotype 2b. IL28B polymorphism was predictive of PEG‐IFN plus RBV combination treatment outcomes in patients infected with genotype 2 and, especially, with genotype 2b. In conclusion, IL‐28B polymorphism affects responses to PEG‐IFN‐based treatment in difficult‐to‐treat HCV patients. J. Med. Virol. 83:871–878, 2011. © 2011 Wiley‐Liss, Inc.